Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Douglas Williams

Physician Assistant, Medical Kailua, HI Physician Assistant

NPI 1033384011 CMS profile 10860407

1051 Keolu Dr Ste 107, Kailua, HI 96734

Open in the dashboard

General payments

$8,136

281 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Douglas Williams of Kailua, HI is reported in the CMS Open Payments database as having received $8,136 across 281 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,501 56
2024 General $1,312 46
2023 General $1,894 76
2022 General $2,562 70
2021 General $868 33

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Douglas Williams
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Douglas Williams were reported at $1,501. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Douglas Williams Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $868 $156 $41–$563 $132
2022 $2,562 $185 $55–$649 $149
2023 $1,894 $199 $58–$717 $160
2024 $1,312 $206 $62–$740 $164
2025 $1,501 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $2,132 83 payments
  2. Regeneron Healthcare Solutions, Inc. $1,592 34 payments
  3. Genzyme Corporation $847 28 payments
  4. Lilly USA, LLC $764 33 payments
  5. LEO Pharma Inc. $505 29 payments
  6. UCB, Inc. $423 15 payments
  7. Atricure, Inc. $359 2 payments
  8. Allergan Inc. $314 8 payments
  9. Pfizer Inc. $220 9 payments
  10. Novartis Pharmaceuticals Corporation $173 9 payments
  11. Other $806 31 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $7,760 274 payments
  2. Travel and Lodging $266 1 payment
  3. Education $109 6 payments
Products named General payments · program years 2021–2025
  1. DUPIXENT Inflammation And Immunology $1,409 26 payments
  2. DUPIXENT Immunology $987 30 payments
  3. RINVOQ $965 28 payments
  4. SKYRIZI $811 35 payments
  5. TALTZ $643 29 payments
  6. OLUMIANT $516 24 payments
  7. ADBRY $464 27 payments
  8. Bimzelx $392 14 payments
  9. SYNERGY ABLATION SYSTEM $359 2 payments
  10. HUMIRA $331 15 payments
  11. Other $2,540 97 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 24 drugs

Part D claims

614

Median for Physician Assistant: 241

Drug cost

$68,925

Median for Physician Assistant: $4,110

Branded share of claims

17.8%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Syringe Dupilumab Brand 14 $52,230
Cephalexin Generic 36 $2,302
Clobetasol Propionate Generic 23 $1,889
Ciprofloxacin Hcl Generic 27 $1,257
Fluorouracil Generic 19 $1,230
Hydrocortisone Generic 51 $935
Triamcinolone Acetonide Generic 59 $914
Liothyronine Sodium Generic 34 $864
Metronidazole Generic 23 $862
Ssd Silver Sulfadiazine Brand 72 $849

The 10 drugs with the highest cost, of 24 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 72 billing codes

Paid by Medicare

$102,229

Of which drugs: $666

Medicare patients

162

Average age 75

Services billed

1,565

87 women, 75 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 62%
Arthritis 38%
Diabetes 25%
Ischemic heart disease 19%
Chronic kidney disease 19%
Atrial fibrillation 15%
COPD 14%
Depression 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 15 58 $39

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $267
  • GENZYME CORPORATION $169
$436 14 —
SKYRIZI
  • AbbVie, Inc. $142
$142 — —
Bimzelx
  • UCB, Inc. $106
$106 — —
DAXXIFY
  • REVANCE THERAPEUTICS, INC. $94
$94 — —
RINVOQ
  • AbbVie, Inc. $89
$89 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

281 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Hawaii

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record